Transformative advancements in immune checkpoint inhibitor therapy for Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Advancements in Immune checkpoint inhibitor (ICI) treatment have greatly changed the way oropharyngeal squamous cell carcinoma (OPSCC) is treated. This paper examines the crucial advancements and their consequences for clinical practice. Initially, the implementation of ICIs, such as pembrolizumab a...
Saved in:
Main Authors: | Iadalin Ryntathiang, Mukesh Kumar Dharmalingam Jothinathan |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-09-01
|
Series: | Oral Oncology Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2772906024004102 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Subacute parkinsonism induced by immune checkpoint inhibitors
by: Lénia Silva, et al.
Published: (2024-12-01) -
Pembrolizumab- induced subacute cutaneous lupus erythematosus in a patient with oropharyngeal squamous cell carcinoma: A case report and literature review
by: Beata Mayer, et al.
Published: (2025-12-01) -
A case of eruptive keratoacanthomas and lichen planus secondary to nivolumab treatment for stage IV melanoma
by: Daniel S. Alicea, MS, et al.
Published: (2025-03-01) -
Hepatic sinusoidal obstruction syndrome (SOS) associated with checkpoint inhibitor therapy
by: Marianna Litterio, et al.
Published: (2024-12-01) -
The role of immunotherapy in the treatment of lip squamous cell carcinoma: A series of six cases and a review of the current literature
by: Ido Amir, et al.
Published: (2024-06-01)